2016-03-15T00:00:00.000-04:00
Aralez infrastructure,0.247347
business development opportunities,0.733063
net revenues,0.434792
POZEN,0.0180092
global specialty,0.480524
financial flexibility,0.733063
specialty pharmaceutical company,0.480524
financial statements,0.248775
new company Aralez,0.644841
non-GAAP R&D expenses,0.270869
potential FDA approval,0.38955
new staff costs,0.247347
sales professionals,0.248255
pricing levels,0.302495
results,-0.126141
non-GAAP SG&A expenses,0.268062
company,0.336153
future events,0.314778
FDA approval,0.38955
non-gaap information,0.326866
forward-looking statements,-0.138858
new strategic direction,0.278002
